BIOME AUSTRALIA LIMITED (BIO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BIO

BIO - BIOME AUSTRALIA LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Household & Personal Products
Debt/EBITDA: -0.78
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.44

24 Jun
2025

0.020

OPEN

$0.42

4.76%

HIGH

$0.44

904,151

LOW

$0.41

TARGET
$0.85 93.2% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
BIO: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 0.8 0.3 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 153.3 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 20202021202220232024
EPS Basic xxxxxxxxxxxx-0.8
DPS All xxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxx13.0 M
Book Value Per Share xxxxxxxxxxxx1.4
Net Operating Cash Flow xxxxxxxxxxxx-0.2 M
Net Profit Margin xxxxxxxxxxxx-12.84 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20202021202220232024
Return on Capital Employed xxxxxxxxxxxx-51.47 %
Return on Invested Capital xxxxxxxxxxxx-44.08 %
Return on Assets xxxxxxxxxxxx-21.09 %
Return on Equity xxxxxxxxxxxx-51.47 %
Return on Total Capital xxxxxxxxxxxx-42.84 %
Free Cash Flow ex dividends xxxxxxxxxxxx-0.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20202021202220232024
Short-Term Debt xxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxx3 M
Price To Book Value xxxxxxxxxxxx42.96

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20202021202220232024
Capex xxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxx0.17 %
Cost of Goods Sold xxxxxxxxxxxx5 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

29/04/2025

1

Buy

$0.85

93.18%

Biome Australia delivered another strong quarterly result, assesses Bell Potter, with adjusted earnings (EBITDA) excluding share-based payments slightly positive at approximately $0.195m, marking the fifth consecutive positive quarter.

Sales grew 40.9% year-on-year but were flat quarter-on-quarter due to seasonal factors, while the Activated Probiotics brand continues to gain traction domestically, highlights the broker.

The analysts observe an expanded ranging in TerryWhite Chemmart ((EBO)) and Priceline ((WES)), and new international wins in Canada, Ireland, the UK, and New Zealand.

The company remains on track for a maiden full-year profit in FY25, suggests the broker, supported by seasonally stronger trading and expectations of increased demand from a predicted record cold and flu season.

Bell Potter retains a Buy rating and 85c target price. The share price has fallen approximately -39% since the 1H25 result, despite the business maintaining strong momentum and delivering improving financial performance, highlights the broker.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.30 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.70 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

BIO STOCK CHART

FNArena News on BIO

1
Rudi’s View: Best Ideas & Conviction Calls

Feb 20 2025 - Rudi's View
2
FNArena Corporate Results Monitor – 19-02-2025

Feb 19 2025 - Australia
3
Rudi’s View: AGL Energy, Bega Cheese, BRG, Harvey Norman, Imdex & Superloop

Feb 06 2025 - Rudi's View
4
Rudi’s View: Cochlear, Guzman y Gomez, SiteMinder, Wesfarmers & Xero

Jan 30 2025 - Rudi's View
5
Rudi’s View: Feb Season’s Best Buys & Key Picks

Jan 23 2025 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
2
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
3
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
4
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
5
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
6
CSL Shares Breaking Free

Jul 23 2024 - Technicals
7
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
8
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
9
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
10
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps